<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hereditary prothrombotic states of clinical importance include factor V Leiden, the prothrombin 20210A mutation, deficiencies of protein C, protein S, or antithrombin, <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e>, and <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Major acquired prothrombotic states include <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, and <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Because most of the hereditary prothrombic states are not established risk factors for <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, routine laboratory testing in most patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> should be limited to complete blood count, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies, and plasma total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Additional testing for factor V Leiden, prothrombin 20210A, antithrombin, protein C, and protein S may be indicated for patients under the age of 50 or those with paradoxical <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in patients with prothrombotic states is similar to that in patients without an identifiable prothrombotic condition, and may include antiplatelet agents, <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, or thrombolytic therapy in patients who otherwise meet eligibility criteria </plain></SENT>
<SENT sid="5" pm="."><plain>The potential benefit of <z:hpo ids='HP_0011010'>chronic</z:hpo> anticoagulation therapy for the primary or secondary prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with prothrombotic states has not been addressed in controlled clinical trials </plain></SENT>
<SENT sid="6" pm="."><plain>Specific therapeutic approaches for the prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> are established for patients with <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e>, <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, and <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo>, and are under investigation for <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> and the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>